We are proud to announce that we have received the Certificate of Suitability (CEP) for Triamcinolone, a key corticosteroid used across dermatologic, ophthalmic, and veterinary treatments.

Granted by the European Directorate for the Quality of Medicines (EDQM), the CEP certifies that our API meets the strict quality benchmarks of the European Pharmacopoeia. This recognition simplifies regulatory pathways across Europe and other stringent markets making it easier for partners to bring effective formulations to patients and professionals.

Triamcinolone is a versatile anti-inflammatory agent. It is widely used in topical treatments for skin conditions like eczema and psoriasis, in ophthalmic preparations to manage ocular inflammation, and in veterinary medicine to treat a range of inflammatory and allergic responses in animals. Its broad-spectrum application makes it a critical component in both human and animal health.

With this CEP approval, Coral reinforces its capability to manufacture high-quality, compliant APIs that meet global demand across multiple therapeutic areas. This milestone reflects our dedication to regulatory excellence and to serving the diverse needs of healthcare systems worldwide.

For more updates on our certified APIs and therapeutic capabilities, follow us on LinkedIn.

‍